Citrine Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$289K Buy
1,105
+30
+3% +$7.69K 0.1% 48
2026
Q2
$271K Buy
1,075
+21
+2% +$4.52K 0.1% 50
2026
Q1
$229K Buy
+1,054
New +$234K 0.1% 51

Other funds holding ABBV

Citrine Capital's ABBV Position: Q3 2026 in Review

Citrine Capital increased its AbbVie (ABBV) stake by 2.8% in Q3 2026, buying an estimated $7.69K and bringing the position to 1,105 shares worth $289K. The position accounts for 0.1% of the portfolio, ranked #48.

Citrine Capital first reported a position in ABBV in Q1 2026 and has held it in 3 quarters since. 4,278 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Citrine Capital held 1,105 shares of AbbVie worth $289K as of Q3 2026.
  • Citrine Capital bought 30 AbbVie shares in Q3 2026, an estimated $7.69K.
  • AbbVie made up 0.1% of Citrine Capital's portfolio in Q3 2026, its #48 holding.
  • Citrine Capital first reported a position in AbbVie in Q1 2026 and has held it in 3 quarters since.
  • 4,278 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Citrine Capital's 13F filing for Q3 2026, filed 14 Oct 2026.